Antigliadin antibodies associated with chronic mucocutaneous candidiasis.
Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency disease clinically characterized by Candida infection of the skin, mucous membranes, or nails that is refractory to traditional treatment. We present a typical case of a 13-year-old boy with an onset of illness at 1 month of age in the form of oral thrush. At age 2-3 years the patient began to have external otitis caused by Candida albicans and recurrent upper respiratory tract infections. Analytical studies detected iron deficiency and circulating antigliadin antibodies. Immunologic findings excluded other possible immunodeficiencies. Significant clinical improvement was produced by therapy with orally administered fluconazole. The significance of antigliadin antibodies is discussed.
Garcia
Yolanda Hidalgo
YH
Departments of Dermatology and Hospital Central de Asturias, Asturias, Spain. narasop@correo.unioui.es
Díez
Santiago Gómez
SG
Aizpún
Lourdes Tricas
LT
Oliva
Narciso Pérez
NP
D000293:Adolescent; D000906:Antibodies / Q000276:immunology*; D000935:Antifungal Agents / Q000627:therapeutic use; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy / Q000276:immunology*; D015725:Fluconazole / Q000627:therapeutic use; D005903:Gliadin / Q000276:immunology*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome
D000906:Antibodies; D000935:Antifungal Agents; D017964:Itraconazole; D015725:Fluconazole; D005903:Gliadin